We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




10 Minute RT-PCR Point-of-Care System Detects Up To 32 Targets Per Sample

By LabMedica International staff writers
Posted on 21 Mar 2024
Print article
Image: The molecular POC system can run up to 32 targets at a time on a single sample in
Image: The molecular POC system can run up to 32 targets at a time on a single sample in

A 10-minute RT-PCR point-of-care (POC) system and respiratory panel are set to change the discussion on next-generation POC testing.

Autonomous Medical Devices Incorporated (AMDI, Santa Ana, CA, USA) is developing its Fast PCR System, a CLIA-waivable RT-PCR POC system that can detect up to 32 targets per sample in less than 10 minutes. The AMDI Fast PCR system is a compact, easy-to-use molecular point-of-care system that utilizes multiplexing capability specifically for CLIA-waived environments. It can run up to 32 targets at a time on a single sample in <10 minutes using a disposable disc without the need for a separate, offline sample preparation. At the core of the AMDI ultrafast system is the company’s Hyperbaric Heating (HBH) sample prep technology combined with its ultrafast PCR chemistry. The HBH technology eliminates the time constraints and costs associated with traditional sample preparation.

Combining HBH with AMDI’s ultrafast thermal cycling allows the test time to stay under 10 minutes regardless of the number of targets put on the test disc. The AMDI ultrafast system is designed to deliver highly sensitive, lab-quality results with the accessibility needed to address the testing needs of both the current and future pandemics. AMDI is also developing the first test panel for the Fast PCR system, targeting the detection of multiple respiratory viruses. The AMDI Respiratory Panel tests for the four most probable viruses that cause respiratory tract infections since the pandemic, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2.

"Our market research indicates that our technology, when combined with cloud connectivity, can revolutionize patient care in the CLIA Waived setting," said David Okrongly, CEO of AMDI.

Related Links:
AMDI

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
New
Microplates
Eppendorf Microplates
New
Parasite Suspension for QC
Cryptosporidium Species Parasite Suspension

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.